Altimmune Reports Q3 GAAP EPS of -$0.15, Missing Estimates by $0.02
Altimmune (ALT) reported third-quarter earnings that fell short of analyst expectations, posting a GAAP earnings per share (EPS) of -$0.15. This result represents a miss of $0.02 compared to consensus estimates. Despite the earnings miss, the company maintains a significant liquidity position, reporting total cash, cash equivalents, and investments of $480 million as of September 30, 2026. The stock has faced downward pressure following recent presentations regarding its pemvidutide candidate for alcohol-use disorder.
Tickers: $ALT
Topics: cash position clinical presentation earnings report EPS miss
Read the full article at Seeking Alpha
Part of the story Altimmune Reports Q3 GAAP EPS of -$0.15, Missing Estimates by $0.02 (3 articles)